Darling Ingredients Introduces Nextida® NxCogni™, the First Targeted Collagen Peptide Designed to Support Clarity and Cognitive Resilience
Business Wire•20/10/2026•16:35 ET
0
Key Highlights
- ➤Darling Ingredients introduced Nextida NxCogni, a non-stimulant collagen peptide ingredient.
- ➤NxCogni contains more than 10 neurosupportive peptides at over 100 times standard collagen concentrations.
- ➤Human clinical trials begin in Dec. 2026, with randomized trials planned for Q1 2027.
- ➤Nextida NxCogni follows the launch of Nextida GC, supporting the body’s natural GLP-1 response.
Expert Statements
Randall C. Stuewe, Chairman and CEO of Darling Ingredients
“NxCogni is the latest example of how Darling Ingredients is redefining what collagen can do”
Randall C. Stuewe, Chairman and CEO of Darling Ingredients
“Through our proprietary innovation platform, we are building a growing portfolio of collagen peptide ingredients that target specific, science-backed benefits.”
Randall C. Stuewe, Chairman and CEO of Darling Ingredients
“Each new addition to the Nextida family expands our understanding of collagen's potential and reinforces our leadership in creating the next generation of nutritional solutions derived from natural collagen.”
Jeroen Colpaert, Executive Vice President at Rousselot
“Many products on the market today rely on stimulants to provide a brief energy spike, but Nextida NxCogni is built differently”
Jeroen Colpaert, Executive Vice President at Rousselot
“By working with the brain’s natural pathways rather than acting as a stimulant, NxCogni is a natural-derived, evidence-based ingredient dedicated to supporting sustained focus and cognitive resilience.”
Darling Ingredients Introduces Nextida(®) NxCogni(™), the First Targeted Collagen Peptide Designed to Support Clarity and Cognitive Resilience
Non-stimulant, collagen-based dietary ingredient to support daily cognitive well-being
Get started
Create a free account to read the full story.